Bhavesh Ashar serves as Chief Operating Officer at TYRA Biosciences, Inc., a clinical-stage biotechnology company pioneering precision medicine for rare diseases and cancers using its proprietary TYRASM platform. With over 25 years of experience in the biopharmaceutical industry, Ashar has built a distinguished career focused on technical operations, manufacturing, and supply chain excellence. He joined TYRA in 2022 to lead the company's operational strategy, overseeing CMC development, manufacturing, quality assurance, and supply chain functions as the company advances its lead candidate, TYRA-300, into clinical trials for rare genetic disorders. Prior to TYRA, Ashar was Senior Vice President of Technical Operations at bluebird bio, where he spearheaded the scale-up of gene therapy manufacturing processes, enabling the company's first commercial launches and achieving key regulatory milestones with the FDA. His earlier roles included Vice President of Global Supply Chain at Biogen, where he optimized global operations for multiple blockbuster products, and leadership positions at Genzyme (now part of Sanofi) and Amgen, driving CMC strategies for complex biologics. Ashar's achievements include successfully navigating multiple product approvals, implementing lean manufacturing initiatives that reduced costs by over 30%, and fostering cross-functional teams to accelerate time-to-market. At TYRA Biosciences, Ashar plays a pivotal role in operationalizing the company's precision therapeutics pipeline, ensuring robust infrastructure to support rapid development and commercialization. His strategic vision emphasizes agility, innovation, and compliance in precision oncology and endocrinology, positioning TYRA for sustainable growth and transformative impact in underserved patient populations.